Active, not recruitingPHASE1, PHASE2NCT05182749
Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis
Studying Shigellosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Intralytix, Inc.
- Principal Investigator
- Alexander Sulakvelidze, PhDIntralytix, Inc.
- Intervention
- bacteriophage(biological)
- Enrollment
- 52 enrolled
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
Collaborators
University of Maryland, Baltimore
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05182749 on ClinicalTrials.govOther trials for Shigellosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07433426The Impact of Shigellosis and Recommended Treatment in ChildrenJohns Hopkins Bloomberg School of Public Health
- RECRUITINGPHASE1NCT05959616Shigella Sonnei 53G Human Infection Study in Kenyan AdultsUniversity of Oxford
- RECRUITINGPHASE2NCT06615375A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate VaccineLimmaTech Biologics AG
- RECRUITINGPHASE1NCT05961059InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and ZambiaLeiden University Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT05121974Tebipenem Trial in Children With ShigellosisInternational Centre for Diarrhoeal Disease Research, Bangladesh